← All trials
NCT06281119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- May 31, 2026
- First posted
- Feb 28, 2024
- Last posted
- Feb 28, 2024
- Enrollment
- 450
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Serum Institute of India Pvt. Ltd.Lead sponsor
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.